IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-27461-8.html
   My bibliography  Save this article

Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy

Author

Listed:
  • S. M. Kamel

    (University Medical Centre Utrecht)

  • C. J. M. Opbergen

    (University Medical Center Utrecht)

  • C. D. Koopman

    (University Medical Centre Utrecht
    University Medical Center Utrecht)

  • A. O. Verkerk

    (University of Amsterdam, Amsterdam University Medical Centers
    University of Amsterdam, Amsterdam University Medical Centers)

  • B. J. D. Boukens

    (University of Amsterdam, Amsterdam University Medical Centers
    University of Amsterdam, Amsterdam University Medical Centers)

  • B. Jonge

    (University of Amsterdam, Amsterdam University Medical Centers)

  • Y. L. Onderwater

    (University Medical Centre Utrecht)

  • E. Alebeek

    (University Medical Centre Utrecht)

  • S. Chocron

    (University Medical Centre Utrecht)

  • C. Polidoro Pontalti

    (University Medical Center Utrecht)

  • W. J. Weuring

    (University Medical Center Utrecht, Utrecht University)

  • M. A. Vos

    (University Medical Center Utrecht)

  • T. P. Boer

    (University Medical Center Utrecht)

  • T. A. B. Veen

    (University Medical Center Utrecht)

  • J. Bakkers

    (University Medical Centre Utrecht
    University Medical Center Utrecht
    University Medical Center Utrecht)

Abstract

The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized by sub-epicardial accumulation of fibrofatty tissue, and a specific drug treatment is currently lacking. Here, we address these issues using a knock-in Phospholamban p.Arg14del zebrafish model. Hearts from adult zebrafish with this mutation display age-related remodeling with sub-epicardial inflammation and fibrosis. Echocardiography reveals contractile variations before overt structural changes occur, which correlates at the cellular level with action potential duration alternans. These functional alterations are preceded by diminished Ca2+ transient amplitudes in embryonic hearts as well as an increase in diastolic Ca2+ level, slower Ca2+ transient decay and longer Ca2+ transients in cells of adult hearts. We find that istaroxime treatment ameliorates the in vivo Ca2+ dysregulation, rescues the cellular action potential duration alternans, while it improves cardiac relaxation. Thus, we present insight into the pathophysiology of Phospholamban p.Arg14del cardiomyopathy.

Suggested Citation

  • S. M. Kamel & C. J. M. Opbergen & C. D. Koopman & A. O. Verkerk & B. J. D. Boukens & B. Jonge & Y. L. Onderwater & E. Alebeek & S. Chocron & C. Polidoro Pontalti & W. J. Weuring & M. A. Vos & T. P. Bo, 2021. "Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-27461-8
    DOI: 10.1038/s41467-021-27461-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-27461-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-27461-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Ioannis Karakikes & Francesca Stillitano & Mathieu Nonnenmacher & Christos Tzimas & Despina Sanoudou & Vittavat Termglinchan & Chi-Wing Kong & Stephanie Rushing & Jens Hansen & Delaine Ceholski & Foti, 2015. "Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy," Nature Communications, Nature, vol. 6(1), pages 1-10, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-27461-8. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.